Pharmafile Logo

The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI

Authored by Paul Reed and Anabelle Gall

- PMLiVE

As we move forward in 2024, the healthcare industry has embraced the idea that AI-generated synthetic patients are here for the long haul. The remarkable ability to utilize artificial patients that mimic real-world patient data addresses crucial unmet needs, making it nearly impossible to envision a future healthcare industry without widespread usage and integration of synthetic patients.

However, we must strike a delicate balance between integrating AI tools into market research and acknowledging the invaluable role of human intelligence in understanding, verifying, supervising and analysing insights. In this article, we delve into the compelling arguments surrounding the opportunities and risks associated with the utilization of AI-generated synthetic patients in healthcare market research.

Read the full article here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Achieving customer centricity – Using immersion techniques to get closer to the pulse of the customer

Director Marc Yates discusses the importance of being customer-centric in the pharmaceutical industry and how immersion techniques in market research can help develop a better understanding of the customer.

The Mobile Revolution – Using mobile Apps to deliver “in-the-moment” market research to global healthcare

Director John Branston investigates the use of mobile research in order to capture immediate detailed, qualitative insights into prescription rationale at the patient level.